secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2024-12-02T23:59:59+00:00
Accession:  0001193125-24-268404
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

RMC-6236 shows 38% ORR in NSCLC, 27-36% in PDAC; median PFS 9.8 mo and 8.5-8.8 mo
--------------------------------------------------------------------------------

- NSCLC efficacy: ORR 38% (15/40), median PFS 9.8 mo, median OS 17.7 mo in RAS G12X pts (cutoff Sept 30, 2024).
- PDAC 2L: ORR 36% (G12X) and 27% (broader RAS); median PFS 8.8 and 8.5 mo; 6-mo OS 100% and 97% (cutoff Jul 23, 2024).
- PDAC safety at 300 mg: 34% Grade ≥3 TRAEs, no Grade 5; median duration 5.2 mo, mean dose intensity 89%.
- NSCLC safety: Grade ≥3 TRAEs 27% overall, 41% at 300 mg; one Grade 4 pneumonitis at 300 mg; median duration 5.5 mo (120-220 mg).
- Combination RMC-6236+RMC-6291 in KRAS G12Ci-experienced CRC: ORR 25% (3/12), DCR 92%; plans for Phase 3 NSCLC trial vs docetaxel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000119312524268404/0001193125-24-268404-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000119312524268404/d169582d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-268404

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer